All In Biotech

Drug Trial Radar · NCT01922050

A Study of Increasing Strengths, Safety and Efficacy of Two Formulas of LEO 43204 on the Face or the Chest in Patients With Actinic Keratosis

Safety and Efficacy of Escalating Doses of Two LEO 43204 Formulations Applied Once Daily for Two Consecutive Days on Full Face or Approximately 250 cm2 (40 in2) on the Chest in Subjects With Actinic Keratosis

Last checked: Nov 20, 2026Latest source record: Mar 6, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 320 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

320

Actual

Start

Oct 2013

Primary completion

Nov 2014

Study completion Nov 2014

Sponsor

Lead sponsor
LEO PharmaIndustry
Sponsor type
Industry
First posted
Aug 14, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Part 1: To identify Maximum Tolerated Dose (MTD) levels of two formulations of LEO 43204 after once daily treatment for two consecutive days Part 2: To evaluate efficacy of two formulations of LEO 43204 in two doses after once daily treatment for two consecutive days compared to vehicle formulations

Conditions

  • Actinic Keratosis

Interventions

  • LEO 43204 Formulation 1Drug

  • LEO 43204 Formulation 2Drug

  • LEO 43204 Formulation 1 Dose XDrug

  • LEO 43204 Formulation 1 Dose YDrug

  • LEO 43204 Formulation 2 Dose XXDrug

  • LEO 43204 Formulation 2 Dose YYDrug

  • Placebo Formulation 1Drug

  • Placebo Formulation 2Drug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1: Number of Participants Experiencing a Dose Limiting Toxicity (DLT) Based on Local Skin Responses (LSRs)Time frame: From Day 1 up to and including Day 8
  2. Part 2: Percent Reduction From Baseline in Actinic Keratosis (AK) Counts (Multiple Imputation)Time frame: At Week 8

Locations

25 sites in 2 countries. Site status is shown where the registry gives one.

  • Omni Dermatology

    Phoenix, Arizona

  • Torrance Clinical Research Institute Inc.

    Lomita, California

  • Dermatology Cosmetic Laser Medical Associates of La Jolla, Inc.

    San Diego, California

  • Leavitt Medical Associates of Florida

    Ormond Beach, Florida

  • Clinical Research Center, Morsani Center for Advanced Healthcare

    Tampa, Florida

  • Research Institute of Deaconess Clinic

    Evansville, Indiana

  • Hudson Dermatology, LLC

    Evansville, Indiana

  • DermAssociates, PC

    Rockville, Maryland

  • Great Lakes Research Group, Inc.

    Bay City, Michigan

  • Henry Ford Medical Center, Dept. of Dermatology

    West Bloomfield, Michigan

  • The Dermatology Group, P.C.

    Verona, New Jersey

  • Mount Sinai School of Medicine

    New York, New York

  • Clinical Trials of Texas, Inc.

    San Antonio, Texas

  • Stratica Medical Inc.

    Edmonton, Alberta, Canada

  • Guildford Dermatology Specialists

    Surrey, British Columbia, Canada

  • Durondel C.P. Inc./Dermatology Clinic

    Moncton, New Brunswick, Canada

  • Ultranova Skincare

    Barrie, Ontario, Canada

  • Co-Medica Research Network Inc.

    Courtice, Ontario, Canada

  • Dermatrials Research Incorporated

    Hamilton, Ontario, Canada

  • The Guenther Dermatology Research Centre

    London, Ontario, Canada

  • Lynderm Research Inc.

    Markham, Ontario, Canada

  • SKiN Centre for Dermatology

    Peterborough, Ontario, Canada

  • K. Papp Clinical Research

    Waterloo, Ontario, Canada

  • XLR8 Medical Research

    Windsor, Ontario, Canada

  • Centre de Recherche Dermatologique du Quebec Metropolitain

    Québec, Quebec, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.